UNVC Quote, Financials, Valuation and Earnings

CVS Health has a net margin of -- compared to UNIVEC's net margin of 0.09%. UNIVEC's return on equity of -- beat CVS Health's return on equity of 6.68%.

UNIVEC has a consensus price target of --, signalling downside risk potential of --. On the other hand CVS Health has an analysts' consensus of $66.26 which suggests that it could grow by 47.5%. Given that CVS Health has higher upside potential than UNIVEC, analysts believe CVS Health is more attractive than UNIVEC.

UNIVEC has a beta of 0.131, which suggesting that the stock is 86.927% less volatile than S&P 500. In comparison CVS Health has a beta of 0.541, suggesting its less volatile than the S&P 500 by 45.901%.

UNIVEC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health offers a yield of 5.92% to investors and pays a quarterly dividend of $0.67 per share. UNIVEC pays -- of its earnings as a dividend. CVS Health pays out 37.54% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UNIVEC quarterly revenues are --, which are smaller than CVS Health quarterly revenues of $95.4B. UNIVEC's net income of -- is lower than CVS Health's net income of $87M. Notably, UNIVEC's price-to-earnings ratio is -- while CVS Health's PE ratio is 11.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UNIVEC is -- versus 0.15x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

First Physicians Capital Group has a net margin of -- compared to UNIVEC's net margin of --. UNIVEC's return on equity of -- beat First Physicians Capital Group's return on equity of --.

UNIVEC has a consensus price target of --, signalling downside risk potential of --. On the other hand First Physicians Capital Group has an analysts' consensus of -- which suggests that it could fall by --. Given that UNIVEC has higher upside potential than First Physicians Capital Group, analysts believe UNIVEC is more attractive than First Physicians Capital Group.

UNIVEC has a beta of 0.131, which suggesting that the stock is 86.927% less volatile than S&P 500. In comparison First Physicians Capital Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

UNIVEC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Physicians Capital Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UNIVEC pays -- of its earnings as a dividend. First Physicians Capital Group pays out -- of its earnings as a dividend.

UNIVEC quarterly revenues are --, which are smaller than First Physicians Capital Group quarterly revenues of --. UNIVEC's net income of -- is lower than First Physicians Capital Group's net income of --. Notably, UNIVEC's price-to-earnings ratio is -- while First Physicians Capital Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UNIVEC is -- versus 1.40x for First Physicians Capital Group. Usually stocks with elevated PS ratios are considered overvalued.

IQVIA Holdings has a net margin of -- compared to UNIVEC's net margin of 7.32%. UNIVEC's return on equity of -- beat IQVIA Holdings's return on equity of 21.99%.

UNIVEC has a consensus price target of --, signalling downside risk potential of --. On the other hand IQVIA Holdings has an analysts' consensus of $249.54 which suggests that it could grow by 24.61%. Given that IQVIA Holdings has higher upside potential than UNIVEC, analysts believe IQVIA Holdings is more attractive than UNIVEC.

UNIVEC has a beta of 0.131, which suggesting that the stock is 86.927% less volatile than S&P 500. In comparison IQVIA Holdings has a beta of 1.486, suggesting its more volatile than the S&P 500 by 48.559%.

UNIVEC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IQVIA Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UNIVEC pays -- of its earnings as a dividend. IQVIA Holdings pays out -- of its earnings as a dividend.

UNIVEC quarterly revenues are --, which are smaller than IQVIA Holdings quarterly revenues of $3.9B. UNIVEC's net income of -- is lower than IQVIA Holdings's net income of $285M. Notably, UNIVEC's price-to-earnings ratio is -- while IQVIA Holdings's PE ratio is 26.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UNIVEC is -- versus 2.41x for IQVIA Holdings. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx has a net margin of -- compared to UNIVEC's net margin of -55.94%. UNIVEC's return on equity of -- beat SCWorx's return on equity of -80.46%.

UNIVEC has a consensus price target of --, signalling downside risk potential of --. On the other hand SCWorx has an analysts' consensus of -- which suggests that it could fall by --. Given that UNIVEC has higher upside potential than SCWorx, analysts believe UNIVEC is more attractive than SCWorx.

UNIVEC has a beta of 0.131, which suggesting that the stock is 86.927% less volatile than S&P 500. In comparison SCWorx has a beta of 2.792, suggesting its more volatile than the S&P 500 by 179.246%.

UNIVEC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SCWorx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UNIVEC pays -- of its earnings as a dividend. SCWorx pays out -- of its earnings as a dividend.

UNIVEC quarterly revenues are --, which are smaller than SCWorx quarterly revenues of $759.7K. UNIVEC's net income of -- is lower than SCWorx's net income of -$425K. Notably, UNIVEC's price-to-earnings ratio is -- while SCWorx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UNIVEC is -- versus 0.71x for SCWorx. Usually stocks with elevated PS ratios are considered overvalued.